1st Sep 2015 15:17
For immediate release | 1 September 2015 |
ABCAM PLC
("Abcam" or "the Company")
Total Voting Rights - Voting Rights and Capital
In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 201,056,588 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.The above figure of 201,056,588 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
Date of Notification: 1 September 2015
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer Laura Taylor, Investor Relations Manager | |
J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce - Nominated Adviser | |
Peel Hunt LLP - Joint Corporate Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking | |
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 800 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L